# Open Label Extension Study of AMX0035 in Patients With ALS

> **NCT03488524** · PHASE2 · COMPLETED · sponsor: **Amylyx Pharmaceuticals Inc.** · enrollment: 90 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** AMX0035

## Key facts

- **NCT ID:** NCT03488524
- **Lead sponsor:** Amylyx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-29
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488524, "Open Label Extension Study of AMX0035 in Patients With ALS". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03488524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*